Emergent BioSolutions (NYSE:EBS) Rating Increased to Buy at StockNews.com

Emergent BioSolutions (NYSE:EBS) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report issued on Tuesday.

EBS has been the subject of several other research reports. Rodman & Renshaw reiterated a “buy” rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a research note on Friday, September 13th. Benchmark boosted their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Price Performance

Shares of Emergent BioSolutions stock opened at $9.97 on Tuesday. Emergent BioSolutions has a twelve month low of $1.42 and a twelve month high of $15.10. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The company has a 50-day simple moving average of $8.63 and a two-hundred day simple moving average of $7.96. The stock has a market capitalization of $540.17 million, a price-to-earnings ratio of -2.43 and a beta of 1.57.

Hedge Funds Weigh In On Emergent BioSolutions

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Emergent BioSolutions by 14.7% in the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock valued at $8,631,000 after buying an additional 436,911 shares in the last quarter. Millennium Management LLC increased its position in Emergent BioSolutions by 5.8% during the 2nd quarter. Millennium Management LLC now owns 946,302 shares of the biopharmaceutical company’s stock worth $6,454,000 after purchasing an additional 52,144 shares in the last quarter. American Century Companies Inc. increased its position in Emergent BioSolutions by 240.9% during the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock worth $6,015,000 after purchasing an additional 623,201 shares in the last quarter. Assenagon Asset Management S.A. increased its position in Emergent BioSolutions by 74.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock worth $6,192,000 after purchasing an additional 316,700 shares in the last quarter. Finally, Marshall Wace LLP increased its position in Emergent BioSolutions by 75.4% during the 2nd quarter. Marshall Wace LLP now owns 542,813 shares of the biopharmaceutical company’s stock worth $3,702,000 after purchasing an additional 233,341 shares in the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.